Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

BACKGROUND: In RELAY, a randomized, double-blind, phase III trial investigating the efficacy and safety of ramucirumab+erlotinib (RAM+ERL) or ERL+placebo (PBO) in patients with untreated, stage IV, epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), RAM+ERL demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Chao-Hua, Lin, Meng-Chih, Wei, Yu-Feng, Chang, Gee-Chen, Su, Wu-Chou, Hsia, Te-Chun, Su, Jian, Wang, Anne Kuei-Fang, Jen, Min-Hua, Puri, Tarun, Shih, Jin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345079/
https://www.ncbi.nlm.nih.gov/pubmed/37329423
http://dx.doi.org/10.1007/s11523-023-00975-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345079/
https://www.ncbi.nlm.nih.gov/pubmed/37329423
http://dx.doi.org/10.1007/s11523-023-00975-5

Ejemplares similares